157 related articles for article (PubMed ID: 25494295)
1. Noninvasive approaches for detecting and monitoring bladder cancer.
Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
Expert Rev Anticancer Ther; 2015 Mar; 15(3):283-94. PubMed ID: 25494295
[TBL] [Abstract][Full Text] [Related]
2. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
3. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
4. Urine tenascin‑C is an independent risk factor for bladder cancer patients.
Guan Z; Zeng J; Wang Z; Xie H; Lv C; Ma Z; Xu S; Wang X; He D; Li L
Mol Med Rep; 2014 Mar; 9(3):961-6. PubMed ID: 24366195
[TBL] [Abstract][Full Text] [Related]
5. Bladder cancer.
Barocas DA; Clark PE
Curr Opin Oncol; 2008 May; 20(3):307-14. PubMed ID: 18391631
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of urothelial carcinoma of the bladder.
Tanaka MF; Sonpavde G
Postgrad Med; 2011 May; 123(3):43-55. PubMed ID: 21566415
[TBL] [Abstract][Full Text] [Related]
7. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
[TBL] [Abstract][Full Text] [Related]
8. Organ preservation in muscle-invasive bladder cancer.
Fernando SA; Sandler HM
Oncology (Williston Park); 2005 Mar; 19(3):334-9; discussion 339-40, 345, 349, 350-3. PubMed ID: 15828550
[TBL] [Abstract][Full Text] [Related]
9. Organ-sparing strategies in the management of invasive bladder cancer.
Yafi FA; Cury FL; Kassouf W
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1765-75. PubMed ID: 19954288
[TBL] [Abstract][Full Text] [Related]
10. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract.
Helpap B
Cancer; 2002 Oct; 95(7):1415-20. PubMed ID: 12237909
[TBL] [Abstract][Full Text] [Related]
11. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.
Dumache R; David D; Kaycsa A; Minciu R; Negru S; Puiu M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):163-7. PubMed ID: 21682190
[TBL] [Abstract][Full Text] [Related]
12. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
[TBL] [Abstract][Full Text] [Related]
13. Pathological possibilities and pitfalls in detecting aggressive bladder cancer.
Mitra AP; Jordà M; Cote RJ
Curr Opin Urol; 2012 Sep; 22(5):397-404. PubMed ID: 22825461
[TBL] [Abstract][Full Text] [Related]
14. ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer.
Gaya JM; López-Martínez JM; Karni-Schmidt O; Bonal DM; Algaba F; Palou J; Villavicencio H; Benson MC; Cordon-Cardo C; Castillo-Martin M
J Urol; 2015 Apr; 193(4):1144-50. PubMed ID: 25444981
[TBL] [Abstract][Full Text] [Related]
15. Combined-modality therapy for bladder cancer.
McCaffrey JA; Bajorin DF; Scher HI; Bosl GJ
Oncology (Williston Park); 1997 Sep; 11(9 Suppl 9):18-26. PubMed ID: 9330404
[TBL] [Abstract][Full Text] [Related]
16. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy.
Shipley WU; Kaufman DS; Heney NM; Althausen AF; Zietman AL
J Urol; 1999 Aug; 162(2):445-50; discussion 450-1. PubMed ID: 10411054
[TBL] [Abstract][Full Text] [Related]
17. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
[TBL] [Abstract][Full Text] [Related]
18. [Bladder carcinoma--a current review].
Engeler DS; Schmid HP
Praxis (Bern 1994); 2003 Jan; 92(4):117-26. PubMed ID: 12632842
[TBL] [Abstract][Full Text] [Related]
19. Current status of radiation therapy and combined-modality treatment for bladder cancer.
Rödel C
Strahlenther Onkol; 2004 Nov; 180(11):701-9. PubMed ID: 15549188
[TBL] [Abstract][Full Text] [Related]
20. Emerging Bladder Cancer Biomarkers and Targets of Therapy.
Netto GJ; Tafe LJ
Urol Clin North Am; 2016 Feb; 43(1):63-76. PubMed ID: 26614029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
